The United States market has experienced a positive trend, rising 2.9% over the last week and 12% over the past year, with earnings projected to grow by 14% annually in the coming years. In this environment, companies like Globus Medical that exhibit strong growth potential and high insider ownership can be particularly appealing as they suggest confidence from those closest to the business.
Top 10 Growth Companies With High Insider Ownership In The United States
| Name | Insider Ownership | Earnings Growth |
| Super Micro Computer (NasdaqGS:SMCI) | 16.2% | 37.4% |
| Duolingo (NasdaqGS:DUOL) | 14.3% | 39.9% |
| AST SpaceMobile (NasdaqGS:ASTS) | 13.4% | 64.6% |
| FTC Solar (NasdaqCM:FTCI) | 27.9% | 61.8% |
| Credo Technology Group Holding (NasdaqGS:CRDO) | 12.1% | 65.1% |
| Astera Labs (NasdaqGS:ALAB) | 15.2% | 44.6% |
| Niu Technologies (NasdaqGM:NIU) | 36% | 82.8% |
| BBB Foods (NYSE:TBBB) | 16.2% | 30.2% |
| Enovix (NasdaqGS:ENVX) | 12.1% | 58.4% |
| Upstart Holdings (NasdaqGS:UPST) | 12.5% | 102.6% |
We'll examine a selection from our screener results.
Globus Medical (NYSE:GMED)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions for musculoskeletal disorders in the United States and internationally, with a market cap of $8.29 billion.
Operations: The company generates revenue primarily from its Medical Products segment, which accounts for $2.51 billion.
Insider Ownership: 17%
Earnings Growth Forecast: 30.7% p.a.
Globus Medical shows strong growth potential, with earnings forecasted to grow significantly at 30.7% annually, outpacing the US market. Recent Q1 earnings report revealed a turnaround from a net loss to a net income of US$75.46 million. The company announced a substantial share repurchase program worth up to $500 million, signaling confidence in its financial health and future prospects despite slower revenue growth forecasts compared to its earnings trajectory.
- Get an in-depth perspective on Globus Medical's performance by reading our analyst estimates report here.
- According our valuation report, there's an indication that Globus Medical's share price might be on the cheaper side.
Toast (NYSE:TOST)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Toast, Inc. operates a cloud-based digital technology platform for the restaurant industry globally and has a market cap of $25.84 billion.
Operations: The company's revenue segment includes Data Processing, which generated $5.22 billion.
Insider Ownership: 18.9%
Earnings Growth Forecast: 31.7% p.a.
Toast demonstrates strong growth potential, with earnings expected to grow significantly at 31.7% annually, surpassing the US market's rate. Despite slower revenue growth at 15.4%, it remains above the market average. The company recently turned profitable, reporting a net income of US$56 million for Q1 2025. Notably, Toast has seen substantial insider buying over the past three months and completed a share buyback program worth US$73.41 million, reflecting insider confidence in its trajectory.
- Take a closer look at Toast's potential here in our earnings growth report.
- According our valuation report, there's an indication that Toast's share price might be on the expensive side.
TXO Partners (NYSE:TXO)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: TXO Partners, L.P. is an oil and natural gas company that specializes in acquiring, developing, optimizing, and exploiting conventional reserves in North America with a market cap of $806.12 million.
Operations: The company's revenue is primarily derived from the exploration and production of oil, natural gas, and natural gas liquids, totaling $299.70 million.
Insider Ownership: 25.2%
Earnings Growth Forecast: 44.6% p.a.
TXO Partners shows promising growth potential, with earnings expected to grow significantly at 44.6% annually, outpacing the US market. Revenue forecasts indicate an 11.2% annual increase, although recent financials show a dip in net income despite higher revenues. The company completed a $175 million follow-on equity offering, leading to substantial shareholder dilution over the past year. However, insider confidence is evident with more shares bought than sold recently and no significant insider selling in three months.
- Click to explore a detailed breakdown of our findings in TXO Partners' earnings growth report.
- Our expertly prepared valuation report TXO Partners implies its share price may be lower than expected.
Seize The Opportunity
- Click here to access our complete index of 190 Fast Growing US Companies With High Insider Ownership.
- Looking For Alternative Opportunities? The end of cancer? These 23 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're here to simplify it.
Discover if TXO Partners might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com